#United States #Elanco #Greenfield #Pet Health #Credelio Quattro

Elanco's Pet Health Revolution with Credelio Quattro

Elanco Animal Health Incorporated (NYSE: ELAN) has recently unveiled remarkable developments in its pet health product line, specifically with the introduction of Credelio Quattro. This innovative treatment has made history by achieving $100 million in net sales in under eight months, making it the fastest blockbuster product in Elanco's history. Notably, it also stands out as one of the quickest to reach such sales milestones within the industry, particularly following a single geographic approval.

Credelio Quattro has positioned itself as a frontrunner in the battle against pets' parasites, offering extensive protection against six different types of parasites: fleas, ticks, heartworm disease, and three intestinal parasites—roundworms, hookworms, and tapeworms. According to Bobby Modi, Executive Vice President of U.S. Pet Health and Global Digital Transformation at Elanco, there is an increasing demand for all-in-one products from both pet owners and veterinarians. The product has already captured approximately 14% of the dollar share in broad-spectrum sales from U.S. veterinary clinics.

As concerns rise about tick-borne diseases like Lyme disease, which has been proliferating due to increasing populations of black-legged ticks in the eastern United States, the significance of effective flea and tick treatments becomes even more evident. Research indicates that the regions with high risk for dogs align closely with areas where humans are testing positive for Lyme disease. Therefore, Credelio Quattro's formula includes lotilaner, which swiftly kills ticks, aiding in the prevention of its transmission to dogs and humans alike.

Veterinarian Dr. Lindsay Starkey, an Associate Professor of Parasitology at Oklahoma State University's College of Veterinary Medicine, emphasizes that pet owners and veterinarians seek reliable and potent solutions for dealing with parasites, and Credelio Quattro fulfills these needs perfectly.

Credelio Quattro is not alone in Elanco's rapidly expanding portfolio. It joins another recently launched product, Experior®, marking the second out of six blockbuster-potential products that have reached the $100 million milestone in annual net sales. Elanco is poised for geographic expansion for Credelio Quattro, with ongoing submissions for approvals in regions like Australia, Canada, the EU, the UK, and Japan, aiming for a global launch starting in 2026.

Zenrelia - An Innovation for Allergic Dermatitis

In tandem with the success of Credelio Quattro, Zenrelia, another Elanco innovation, has launched in the European Union and Great Britain. This once-daily oral Janus kinase (JAK) inhibitor is designed to effectively control itching and inflammation arising from allergic dermatitis in dogs over twelve months of age.

Dr. Victoria Robinson, a European Specialist in Veterinary Dermatology, believes that Zenrelia will significantly enhance the bond between pet owners and their pets by improving the quality of life amid treatment for skin allergies. Currently, the product is not only available in Europe but also in Brazil, Canada, Japan, and the United States, suggesting a strong international appeal and market acceptance.

In conclusion, Elanco's commitment to advancing pet health through innovative solutions is evident in the successful launch of both Credelio Quattro and Zenrelia. With a blend of extensive protection and a user-friendly approach, these products demonstrate Elanco's dedication to enhancing the well-being of pets and their owners. As the company seeks to expand these products globally, the future looks promising for pet healthcare innovations from Elanco.

For more information on these products or to inquire about pet health solutions, visit Elanco's website.